ZUSDURI's accelerating launch trajectory (109% QoQ) validates the blockbuster thesis and drives the beat. Watch for continued site-of-care expansion and repeat prescriber growth in Q2. The maintained JELMYTO guidance and controlled OpEx provide a clean setup. Key catalysts ahead: UGN-103 NDA submission (H2 2026) and AUA KOL panel on May 17.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $26.25entry
- T+1 · 6mo ago +1.30%α +1.63% · $26.59
- T+5 · 6mo ago +13.52%α +12.39% · $29.80
- T+20 · 6mo ago +1.33%α −1.45% · $26.60
- T+60 · 4mo ago +45.68%α +43.62% · $38.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by ZUSDURI's launch ($29.2M, +109% QoQ) and JELMYTO growth ($21.7M, +7% YoY). Net loss narrowed to $23.6M ($0.47/share) from $43.8M ($0.92/share) a year ago, beating the consensus EPS estimate of -$0.48. The company maintained JELMYTO revenue guidance of $97-101M and operating expense guidance of $240-250M for 2026.
Key Financial Metrics
Key Facts
- Total revenue $51.0M vs $20.3M YoY (+152%), beating consensus $44.8M
- ZUSDURI net product revenue $29.2M in first full quarter of launch (109% QoQ growth)
- JELMYTO revenue $21.7M (+7% YoY), in line with full-year guidance of $97-101M
- Net loss $23.6M ($0.47/share) vs consensus -$0.48, a beat
- Cash and equivalents $140.3M; $200M debt facility from Pharmakon refinanced existing debt
- UGN-103 NDA submission on track for H2 2026; UGN-104 Phase 3 enrollment expected by end of 2026
- 972 activated sites of care, 256 unique ZUSDURI prescribers as of March 31, 2026
Financial Impact
Revenue beat consensus by $6.2M (13.8%); EPS beat consensus by $0.01 (2.1%)
Risk Factors
- ZUSDURI adoption may decelerate as early adopter pool saturates
- SG&A expenses rose 47% YoY to $51.5M, outpacing revenue growth rate
- Shareholders' deficit of $124.3M; reliance on debt financing for operations
- UGN-103/104 clinical and regulatory timelines could slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288758 |
Track record
16 reports on URGN
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
- Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
- Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers